New drugs for RA, psoriasis, type 1 diabetes and Crohn's disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%